Chemotherapy Induced Peripheral Neurotoxicity (CIPN): Why Should we Care

Last updated: July 24, 2025
Sponsor: University of Milano Bicocca
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04986891
CIPN COST
  • Ages > 18
  • All Genders

Study Summary

This is a pilot, observational, cross-sectional, study on socio-economic burden related to chemotherapy-induced peripheral neurotoxicity (CIPN). Investigators will collect CIPN healthcare related costs on a detailed clinical patient-level. As a sub-study, data obtained in this cross-sectional study, will be compared with administrative larger datasets on patients affected by cancer. The aim is to run a test for potential proxy variables which are available in larger administrative datasets, even if not directly measuring CIPN, to learn more about the impact of CIPN.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Cancer patients with this characteristics:

  2. at least 75 consecutive subjects sent for a neurological evaluation before 1stchemotherapy cycle (TNSc score equal to 0 which means no neuropathy);

  3. at least 75 consecutive subjects sent for a neurological evaluation due tostable CIPN condition (CIPN defined as TNSc > or = 1) after chemotherapycompletion (at least 2 months off treatment).

  4. Male and female subjects who are 18 years of age or older.

  5. Subjects freely provide informed consent by signing and dating an informed consentform prior to study entry.

  6. Subjects must be willing to complete all study-related activities and follow-upvisits required by the protocol.

  7. Subjects must have a Karnofsky performance score greater than or equal to 70.

Exclusion

Exclusion Criteria:

  1. Concomitant neurologic conditions (e.g., brain tumor, spinal or brain metastases)that would interfere or complicate the assessments.

  2. Severe depression that in the opinion of the Investigator would complicate theassessments.

  3. Subjects who are currently receiving another medication other than antineoplasticchemotherapy drugs that has known potential to produce neurologic peripheral nervetoxicity (e.g., metronidazole, isoniazid, amiodarone, antiretroviral medications).

  4. Subjects who suffer from another medical condition that can cause neuropathy (e.g.,diabetes)

  5. Subjects with any other condition, which, in the investigator's judgment, mightdecrease the chance of obtaining satisfactory data to achieve the objectives of thestudy.

Study Design

Total Participants: 150
Study Start date:
July 31, 2021
Estimated Completion Date:
December 31, 2025

Study Description

This is an observational, cross-sectional, pilot study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients, aiming at ascertaining the socio-economic burden related to CIPN.

The study will collect the following information:

  • General medical and oncological history

  • Neurological assessment formalized via:

    • NCI-CTC v.5 sensory and motor

    • PI-NRS

    • DN4

    • TNSc©

    • Jamar grooved Pegboard test

  • Patient reported outcome measures related to CIPN:

    • FACT-GOG NTX v.4©

    • EORTC CIPN20©

  • Socio-economic framework: demographic characteristics and working conditions

A sub-study is also planned. For this purpose, a comparison with administrative databases, and in particular the data related to cancer patients, will be performed. Unlike the data adopted in the main analysis of the cross-sectional study, the data provided by administrative datasets do not include direct information on CIPN. Investigators will study whether administrative datasets include variables that could be adopted as proxy for CIPN. It will test the reliability of these proxy variables by comparing the expected distribution of CIPN patients in the latter dataset, with the observed distribution in the outpatient dataset - given specific characteristics of the patients. An analysis of this kind would support the activity of policy makers engaged in the treatment of cancer-related problems.

Study Design: at least 75 consecutive patients who suffer from CIPN and at least 75 consecutive patients before chemotherapy will be enrolled to gain precise information on CIPN severity and its impact on socio-economic indicators. Subjects will be evaluated once, after obtaining written informed consent. A trained investigator will perform the selected healthcare-assessed scales and supervise the patient-completed measures.

Connect with a study center

  • ASST Monza

    Monza, 20900
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.